We are currently evaluating our biotherapeutic TNB-383B for the treatment of multiple myeloma in a Phase 1 study. TNB-383B is a multi-specific antibody we are developing that targets both CD3 (a protein found on the surface of human T cells) and BCMA (a protein overexpressed on the surface of tumors). In preclinical studies, TNB-383B has been shown to be both safe and effective in stimulating the immune system to attack cancerous cells.
A Study of TNB-383B in Subjects with Relapsed or Refractory Multiple Myeloma
Condition: Relapsed or refractory multiple myeloma
Phase: Phase 1
The purpose of this study is to evaluate the safety, tolerability, PK and PD profiles of escalating doses of TNB-383B.
For more information and additional resources, visit:
– American Cancer Society
To learn more about our clinical study of TNB-383B in patients with multiple myeloma, visit www.ClinicalTrials.gov.